Despite disappointing results from one late stage clinical trial, Acadia Pharmaceuticals (Nasdaq: ACAD) and Biovail will continue development of its Parkinson's disease drug pimavanserin. The stock price rose 25 cents to close at $1.90.
Acadia Continues Development Of Pimavanserin
October 06, 2009 at 17:49 PM EDT
